-
China’s Kingfriend Biochemical Acquires U.S.-Listed Adalimumab Biosimilar Yusimry for USD 40 Million
•
Nanjing Kingfriend Biochemical Pharmaceutical Co., Ltd (SHA: 603707), a Chinese pharmaceutical company, has announced the acquisition of Yusimry, a biosimilar of adalimumab, from U.S. firm Coherus Biosciences (NASDAQ: CHRS) for a purchase price of USD 40 million. This deal includes the marketing approval, patents, and related assets of the drug,…
-
Nanjing Kingfriend Biochemical Gets FDA Nod for Dacarbazine Manufacture at Sagent Facility
•
Nanjing Kingfriend Biochemical Pharmaceutical Co., Ltd (SHA: 603707), a Chinese pharmaceutical company, has announced that it has received an approval letter from the U.S. Food and Drug Administration (FDA) for its dacarbazine (200 mg/vial) product. The product is approved for manufacturing at a facility operated by Sagent (China) Pharmaceuticals Co.,…
-
Tonghua Dongbao Pharmaceuticals Partners with King-Friend Biochemical on Insulin Development
•
China-based Tonghua Dongbao Pharmaceuticals (SHA: 600867) has entered into a partnership with fellow Chinese firm Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd (603707.SH). The collaboration focuses on the development and manufacturing of insulin glargine, insulin aspart, and insulin lispro, with the goal of filing for approval with the US FDA. King-Friend…
